Physician profile
Leslie Miller
NPI 1114937075
$4,413.24
in general payments reported to CMS, 2019-2025
23 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2021: $94.86 · 2022: $230 · 2023: $145 · 2024: $2,263 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555 · Travel and Lodging: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.26 |
| Travel and Lodging | $1,154.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,460.53 | 2024-2025 | |
| Cvrx, INC. | $510.49 | 2024-2025 | Barostim Neo System |
| Biocardia, INC. | $272.96 | 2019 | |
| Alnylam Pharmaceuticals INC. | $242.66 | 2024-2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.37 | 2022-2025 | Jardiance |
| Abbott Laboratories | $227.72 | 2021-2025 | Cardiomems |
| Pfizer INC. | $202.10 | 2021-2025 | |
| Impulse Dynamics (USA) INC. | $187.40 | 2024 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $177.90 | 2019-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $163.14 | 2022-2024 | Verquvo, Winrevair |
| Novartis Pharmaceuticals Corporation | $154.06 | 2021-2025 | |
| Procyrion, INC. | $140.72 | 2025 | Aortix System |
| Actelion Pharmaceuticals US, INC. | $140.46 | 2024-2025 | Opsumit, Uptravi |
| Bridgebio Pharma, INC. | $74.87 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.34 | 2024-2025 | Lifevest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37.11 | 2022-2024 | Repatha |
| Kestra Medical Technology Services, INC. | $29.48 | 2023 | Assure Wcd |
| Daiichi Sankyo INC. | $26.70 | 2023 | Injectafer |
| Scpharmaceuticals INC. | $24.51 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $19.27 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $14.37 | 2025 | Camzyos |
| Novo Nordisk INC | $14.08 | 2025 | Ozempic |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.